• 1. Excellent kinetics of single-phase Gd-doped ceria fuel electrodes in solid oxide cells?
  Andreas Nenning,Manuel Holzmann,Jürgen Fleig,Alexander K. Opitz Mater. Adv., 2021,2, 5422-5431
• 2. Excellent peroxidase mimicking property of CuO/Pt nanocomposites and their application as an ascorbic acid sensor?
  Xinhuan Wang,Shuangfei Cai,Cui Qi Analyst, 2017,142, 2500-2506
• 3. Fast synthesis of red Li3BaSrLn3(WO4)8:Eu3+ phosphors for white LEDs under near-UV excitation by a microwave-assisted solid state reaction method and photoluminescence studies
  Bo Wei,Zhenyu Liu,Chen Xie,Shu Yang,Wentao Tang,Aiwei Gu,Wing-Tak Wong,Ka-Leung Wong J. Mater. Chem. C, 2015,3, 12322-12327
• 4. Evolution study of photo-synthesized gold nanoparticles by spectral deconvolution model: a quantitative approach
  Chung-Sung Yang,Mong-Shian Shih,Fang-Yi Chang New J. Chem., 2006,30, 729-735
• 5. Excited state potential energy surfaces and their interactions in FeIVO active sites
  Shaun D. Wong,Edward I. Solomon Dalton Trans., 2014,43, 17567-17577

Introduction to 5-Bromo-1,3-dimethyl-1H-pyrazolo[3,4-c]pyridine (CAS No. 1434054-03-1)

5-Bromo-1,3-dimethyl-1H-pyrazolo[3,4-c]pyridine, identified by its Chemical Abstracts Service (CAS) number 1434054-03-1, is a heterocyclic compound that has garnered significant attention in the field of pharmaceutical and medicinal chemistry. This compound belongs to the pyrazolopyridine class, a structural motif known for its broad biological activity and potential therapeutic applications. The presence of a bromine substituent at the 5-position and methyl groups at the 1 and 3 positions enhances its utility as a versatile scaffold for drug discovery and molecular probe development.

The pyrazolo[3,4-c]pyridine core is a fused bicyclic system consisting of a pyrazole ring linked to a pyridine ring. This structural configuration imparts unique electronic and steric properties, making it an attractive scaffold for designing compounds with specific biological targets. The bromine atom in 5-Bromo-1,3-dimethyl-1H-pyrazolo[3,4-c]pyridine serves as a handle for further chemical modifications, such as cross-coupling reactions, allowing chemists to append diverse functional groups and explore novel derivatives.

In recent years, there has been a surge in research focused on developing small-molecule inhibitors targeting various diseases, including cancer, inflammation, and neurodegenerative disorders. The 5-Bromo-1,3-dimethyl-1H-pyrazolo[3,4-c]pyridine scaffold has emerged as a promising candidate due to its ability to interact with multiple biological pathways. For instance, studies have demonstrated its potential in modulating kinases and other enzymes involved in cell signaling pathways relevant to cancer progression.

One of the most compelling aspects of 5-Bromo-1,3-dimethyl-1H-pyrazolo[3,4-c]pyridine is its role as an intermediate in the synthesis of more complex pharmacophores. Researchers have leveraged its structural features to develop inhibitors of protein-protein interactions and to create molecules with enhanced binding affinity to therapeutic targets. The brominated pyrazolopyridine derivative has been particularly useful in generating libraries of compounds for high-throughput screening (HTS) campaigns aimed at identifying novel drug candidates.

The pharmaceutical industry has shown considerable interest in this compound due to its synthetic accessibility and biological relevance. Several academic and industrial groups have reported the use of 5-Bromo-1,3-dimethyl-1H-pyrazolo[3,4-c]pyridine in lead optimization programs. These efforts have led to the discovery of several promising analogs with improved pharmacokinetic profiles and reduced toxicity. The compound's versatility has also made it a valuable tool in medicinal chemistry for designing molecules with targeted therapeutic effects.

Recent advancements in computational chemistry have further enhanced the utility of 5-Bromo-1,3-dimethyl-1H-pyrazolo[3,4-c]pyridine as a scaffold for drug design. Molecular docking studies have revealed its potential binding interactions with various protein targets, providing insights into its mechanism of action. These computational approaches have complemented experimental efforts by predicting novel derivatives with optimized binding affinities and selectivity.

The synthesis of 5-Bromo-1,3-dimethyl-1H-pyrazolo[3,4-c]pyridine involves multi-step organic transformations that highlight its synthetic flexibility. The process typically begins with the condensation of appropriately substituted hydrazines with ketones or aldehydes to form the pyrazole ring. Subsequent functionalization steps introduce the bromine atom and methyl groups at the desired positions. These synthetic strategies have been refined over time to achieve high yields and purity levels suitable for pharmaceutical applications.

In conclusion, 5-Bromo-1,3-dimethyl-1H-pyrazolo[3,4-c]pyridine (CAS No. 1434054-03-1) represents a significant advancement in medicinal chemistry due to its structural versatility and biological activity. Its role as a key intermediate in drug discovery underscores its importance in developing novel therapeutic agents. As research continues to uncover new applications for this compound, it is likely to remain a cornerstone in the design of next-generation pharmaceuticals.

• 1434054-04-2(5-Bromo-2,3-dimethyl-2H-pyrazolo[3,4-c]pyridine)
• 929617-30-1(5-Bromo-3-methyl-1H-pyrazolo[3,4-c]pyridine)
• 1706459-20-2(1,3-dimethyl-1H-pyrazolo3,4-cpyridine)
• 1337880-46-2(5-Bromo-1-methyl-1H-pyrazolo[3,4-c]pyridine)
• 2089292-88-4(5-bromo-2-methyl-pyrazolo[3,4-c]pyridine)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)